In re Merck Vytorin/Zetia Securities Litigation

Plaintiffs allege that Defendants gave false or misleading information about the efficacy of the drugs Vytorin and Zetia.  As a result of this misinformation, the price of Defendant's securities was artificially increased.

1. Final Approval granted.
2. All objections were overruled.
3. The Orloff Objectors and Objector DeJulius appealed the Final Approval.
4. Plaintiffs motioned for an appeal bond of $50,000 ($25,000 in costs and $25,000 in administrative delays).
5. The $50,000 appeal bond was GRANTED.
6. Objector-Appellant DeJulius posted the appeal bond in full, but motioned for reconsideration, contending that the bond was excessive.
7. The Court denied Objector-Appellant DeJulius' motion to reconsider, noting that he had failed to oppose the initial motion and that his motion to reconsider was deficient under Local Civil Rule 7.1.
8. The Orloff and DeJulius appeals were voluntarily dismissed.

1. Attorneys' fees are excessive.
   • Lodestar calculation lacks sufficient justification.

NOTE:  Attorney Palmer filed his appearance on the appeal.

1. Attorneys' fees are excessive.

NOTE:  Attorney Cochran was listed as the "remitter" on the cashier's check for payment of the appeal bond.